Rheumatoid Arthritis: Abatacept vs. TNF Inhibitors

We are comparing a new treatment strategy using abatacept to the standard TNF inhibitors for patients with rheumatoid arthritis. The goal is to see which approach helps more patients achieve remission.

6-12 months≤5 visitsConfirmation phase (III)No PlaceboStandard MedicinesInjectionInternal MedicineRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Orencia
Orencia is a medicine used to treat rheumatoid arthritis and related conditions by helping reduce joint inflammation and pain.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Abatacept
Abatacept is a substance that reduces immune system overactivity to treat autoimmune conditions such as rheumatoid arthritis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
Department of rheumatology
Bordeaux, France
Centre Hospitalier Universitaire De Caen Normandie
Rheumatology
Caen, France
Centre Hospitalier Jean Rougier
Department of Rheumatology
Cahors, France
Sponsor: University Hospital Montpellier
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.